Maxim Batov

Dr. Maxim Batov

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
AAAmina M. Alieva
Amina M. Alieva
NTNatalia V. Teplova
Natalia V. Teplova
MBMaxim Batov
Maxim Batov
KVKira V. Voronkova
Kira V. Voronkova
RVRamiz K. Valiev
Ramiz K. Valiev
ШМШнахова Лидия Мухамедовна
Шнахова Лидия Мухамедовна
According to many studies, inflammation plays a very significant role in the pathogenesis of heart failure. Many studies have demonstrated an increase in circulating levels of inflammatory markers and cytokines such as C-reactive protein, tumor necrosis factor-a (TNF-a), and interleukins. C-reactive protein is produced in the liver in response to stimulation by various cytokines, mainly interleukin-6, and is a member of the pentraxin superfamily. Pentraxin-3, which is a long pentraxin, has a C-terminal domain of pentraxin similar to the classic short pentraxins, but differs from them in the presence of an unrelated long N-terminal domain. Various cell types can produce pentraxin-3 when exposed to primary inflammatory signals such as interleukin-1, tumor necrosis (TNF-a), oxidized low density lipoprotein, and microbial fragments (eg, lipopolysaccharide, lipoarabinomannans). Data in experimental animal models have demonstrated that pentraxin-3 can play cardioprotective and atheroprotective roles through its influence on the inflammatory process. Pentraxin-3 has been studied in several clinical protocols as a potential biomarker for cardiovascular disease.

1 January 2022 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
AAA.M. Alieva
A.M. Alieva
ASA.V. Sozykin
A.V. Sozykin
VLVera Lyalina
Vera Lyalina
ESE.A. Skripnichenko
E.A. Skripnichenko
NTN.V. Teplova
N.V. Teplova
INIGOR G. NIKITIN
IGOR G. NIKITIN
ВИЧ-ассоциированные заболевания внутренних органов достаточно многообразны, среди них именно патология сердечно-сосудистой системы является одной из непосредственных причин гибели пациентов с ВИЧ-инфекцией. Наблюдательные исследования показали, что ВИЧ-инфицированные лица имеют высокий риск неблагоприятных сердечно-сосудистых событий по сравнению с остальной популяцией. Сердечно-сосудистые заболевания, обусловленные атеросклерозом, в том числе инфаркт миокарда и инсульт, представляют одну из основных причин смертности среди ВИЧ-положительных больных. Ряд исследований указывают на ускорение процессов атерогенеза вследствие ВИЧ-инфекции. В качестве возможных причин обсуждаются как прямое воздействие ВИЧ, так и другие факторы, которые имеют место у данной категории лиц: побочные эффекты антиретровирусной терапии, злоупотребление наркотическими средствами, сопутствующие заболевания, связанные с ВИЧ. Помимо специфических факторов риска у пациентов с ВИЧ-инфекцией могут присутствовать и традиционные — курение, гиподинамия, ожирение, гиперхолестеринемия. Результаты различных исследований показывают, что существует большой научный и практический интерес к проблеме атеросклероза у пациентов с ВИЧ-инфекцией.

Verified
Journal Article
Open access
PDF file
GDGrigory Demyashkin
Grigory Demyashkin
KEKogan Evgenija
Kogan Evgenija
TDTatiana Demura
Tatiana Demura
AGAnastasia Guzik
Anastasia Guzik
DBDmitriy Belokopytov
Dmitriy Belokopytov
AKAndrei Kaprin
Andrei Kaprin
Breast cancer is one of the most common malignancies worldwide, affecting 2.3 million and causing 670,000 deaths in women annually. However, data indicate that the risk of developing breast cancer decreases with pregnancy at a young age, and each subsequent pregnancy further reduces the risk by approximately 10%. One of the characteristics inherent in both the mammary gland epithelium in pregnant women and luminal epithelial adenocarcinomas is the increased expression of NIS—the sodium/iodide symporter, whose defective cytoplasmic forms possess pro-oncogenic properties. Therefore, the analysis of the degree of influence of pregnancy on NIS expression in breast cancer cells is of medical interest. The aim of this study is to conduct a comparative morphological analysis of NIS expression in breast cancer cells according to the number of pregnancies of each patient. This study included 161 patients with triple-negative breast cancer who visited the P.A. Herzen Moscow Oncology Research Institute from 2020 to 2023. Immunohistochemical examination was performed using antibodies to NIS. The gravidity status of women was determined based on provided medical documentation. The degree of NIS expression was assessed using a modified Gainor scale. Statistical analysis was performed using mean and standard deviation (SD) depending on the normality of the distribution (Lilliefors test: p > 0.20); a p-value ≤ 0.05 was considered statistically significant. The degree of correlation between variables was assessed using Kendall’s tau rank correlation coefficient. A weak to moderate negative correlation (τ: −0.369) was found between the number of pregnancies and the degree of NIS expression in triple-negative breast cancer cells. In patients with triple-negative breast cancer, a weak to moderate negative correlation was found between the degree of NIS expression and gravidity status. The discovered phenomenon is likely due to the terminal differentiation of the mammary gland epithelium that occurs during pregnancy. This may potentially indicate the suppression of pro-oncogenic properties of atypical cells developed from the epithelium that has undergone terminal differentiation.

9 June 2023 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
MSM. V. Sedova
M. V. Sedova
MBMaxim Batov
Maxim Batov
VTV. S. Tretyak
V. S. Tretyak
AKA. A. Kolomeytseva
A. A. Kolomeytseva
VKV. M. Khomyakov
V. M. Khomyakov
AKAndrei Kaprin
Andrei Kaprin
Gastric cancer (GC) is the fifth most common malignant neoplasm in the world among all malignant tumors. Currently, the “gold” standard of treatment for patients with non‑metastatic cancer of the stomach and esophageal–gastric junction is surgical treatment, which is complemented by perioperative chemotherapy according to the FLOT scheme, which includes four courses of therapy before surgery and four after. However, according to statistics, less than half of patients complete all adjuvant courses of FLOT chemotherapy due to the high toxicity of the regimen and a decrease in the functional status of patients in the postoperative period. In this regard, studies are being conducted to study the tolerability of total neoadjuvant chemotherapy, when all courses are held at the preoperative stage in order to carry out all stages of treatment in full. International studies have shown the results of the use of targeted (ramucirumab, trastuzumab, pertuzumab), immune drugs (pembrolizumab, nivolumab, ipilimumab), S‑1 in combination with chemotherapy as part of the combined treatment of gastric and esophageal‑ gastric junction cancer. The emergence of new therapeutic agents previously studied in metastatic GC may change approaches to the treatment of localized and locally advanced GC.The review presents the features of perioperative therapy regimens in patients with resectable gastric and esophageal‑ gastric junction cancer in order to reduce the frequency of local and long‑term relapses and improve further prognosis.

23 August 2023 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
MSM. V. Sedova
M. V. Sedova
MBMaxim Batov
Maxim Batov
AKA. A. Kolomeytseva
A. A. Kolomeytseva
VKV. M. Khomyakov
V. M. Khomyakov
NVN. N. Volchenko
N. N. Volchenko
AFA. A. Fedenko
A. A. Fedenko
Purpose. To study the efficacy and safety of total neoadjuvant chemotherapy (NACT) with the FOLFIRINOX regimen for locally advanced gastric (GC) and cardioesophageal junction (CEJ) cancer.Patients and methods. Patients with histologically confirmed locally advanced gastric adenocarcinoma and CEJ, clinical stage cT3 or higher and/or regional lymph node involvement (cN+), without evidence of distant metastasis were included in our open-label, single-centre, non-randomised study. In the FLOT control group, patients received 4 courses preoperatively and 4 postoperatively with follow-up. I In the FOLFIRINOX group 8 courses of chemotherapy were administered in neoadjuvant mode, followed by surgery and observation. The tumor regression grade was assessed in accordance with Becker, Mandard and G. A. Lavnikova scales.Results. The study included 136 patients, 119 of whom started treatment according to the protocol (ITT population). Fiſty-nine patients were enrolled into the FLOT group and 60 into the FOLFIRINOX group. One-year progression-free survival (PFS) was 67,5 % in the FLOT group and 90,4 % in the FOLFIRINOX group (p = 0,29). The estimated 2-year PFS in the FLOT group was 61,4 % [95 % CI, 48,4–77,9 %]. Median PFS and overall survival (OS) were not reached. The incidence of events (progression or death) was lower in the FOLFIRINOX group (odds ratio [OR] 0,40 [95 % CI 0,16–0,97, p = 0,047]). Adverse prognostic factors regardless of treatment were lymphatic (L1), vascular (V1) and perineural invasion (Pn1), and regional lymph node involvement aſter chemotherapy (ypN+) [p = 0,046; p = 0,014; p = 0,0021; p = 0,04, respectively]. There was no correlation between pathological complete response and survival rates.Conclusion. Total neoadjuvant chemotherapy with the FOLFIRINOX regimen for locally advanced GC/ CEJ demonstrated comparable to the perioperative FLOT one-year PFS rate. No association was found between tumor regression grade and survival outcomes.

30 October 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
GDGrigory Demyashkin
Grigory Demyashkin
AGAnastasia Guzik
Anastasia Guzik
MPMikhail Parshenkov
Mikhail Parshenkov
DBDmitriy Belokopytov
Dmitriy Belokopytov
VSVladimir Shchekin
Vladimir Shchekin
AKAndrei Kaprin
Andrei Kaprin
Background: Sodium/iodide symporter (NIS) is a membrane protein involved in iodide transport into cells, making it a key component of thyroid physiology and radioiodine therapy for thyroid cancer. Although NIS is expressed in many extrathyroidal tissues, including breast tumors, its functional role and prognostic significance in these contexts remain a subject of active investigation. Understanding the mechanisms regulating NIS, its influence on cellular processes such as migration and metastasis, and its connection with transcription factors like FOXA1 could contribute to the development of new therapeutic strategies for breast cancer treatment. This study aims to investigate the correlation between sodium/iodide symporter (NIS) expression and response to neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC). Methods: The current retrospective study included 161 TNBC patients who received neoadjuvant chemotherapy followed by mastectomy. NIS expression was assessed via immunohistochemistry, graded semi-quantitatively from 0 to 3+. The Residual Cancer Burden (RCB) scale was used to evaluate the response to chemotherapy. Statistical analysis included Lilliefors tests and Kendall’s tau correlation coefficient. Publicly available Cancer Genome Atlas datasets were analyzed to assess the relationship between NIS and FOXA1 expression. Results: NIS immunopositivity was observed in 69.5% of TNBC samples compared to 63.3% GATA-3-positive and 31.0% of Mammaglobin-positive samples. While no significant correlation was found between NIS expression and age, TNM stage, or Ki-67, a statistically significant moderate positive correlation (τ = 0.481, p < 0.01) was identified between NIS expression and RCB index, indicating that higher NIS expression was associated with a poorer response to neoadjuvant chemotherapy. TCGA data analysis revealed a statistically significant increase in NIS mRNA expression in FOXA1-mutated TNBC samples compared to FOXA1-wild-type samples (p < 0.05). Younger patients exhibited higher Ki-67 levels (τ = −0.416, p < 0.05). Conclusions: Higher NIS expression correlates with chemoresistance to neoadjuvant chemotherapy in TNBC patients. This phenomenon may be linked to FOXA1 activity, suggesting that NIS may represent a potential biomarker for chemoresistance in TNBC. The inverse correlation between patient age and Ki-67 levels may be associated with a different mutational landscape in younger patients.